Sites in Los Angeles and near San Francisco California are enrolling people with severe SCD for a trial to test a gene ...

CRISPR gene therapy trial for sickle cell disease begins, offering hope for a potential cure by targeting the genetic root of ...

The CRISPR-SCD trial is the first clinical attempt to use a non-viral delivery approach to directly correct the sickle cell ...

UCSF Benioff Children’s Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell ...

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech ... Nobel Prize for chemistry winner Jennifer Doudna among its founders – is getting ...

UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell ...

The genome-editing technology can be supercharged by artificial intelligence—and the results are already being felt.

The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 gene-editing technology in humans to directly correct the genetic mutation ... It will combine CRISPR technology developed at IGI – a ...

Genome editing with various CRISPR-Cas molecule complexes has progressed rapidly in recent years. Hundreds of labs around the world are now working to put these tools to clinical use and are ...

基因编辑工具 CRISPR 的发明者之一 Jennifer Doudna 表示，这项技术将通过提供更适应炎热、干旱、潮湿或其他极端气候条件的作物和动物，帮助世界应对 ...

Thanks to CRISPR ... its gene-editing function continuously. "With a continuous expression, this will lead to immunogenicity in humans because a human body will recognize the Cas9 positive ...

A lab scientist peering into a microscope focused on gene editing technology. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a ...